Healthcare spending rises every year, yet treatment for diseases like cancer remains uncertain. The “one-size-fits-all” approach burdens patients with costly, exhausting therapies. Personalized medicine (PM) offers a solution by identifying biomarkers that predict treatment response, but progress is hindered by high costs and biased funding.